The DOI matches its Crossref record; 332 of the 332 references it cites were found in a registry or an index.
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
Open accessAbstract
The platinum drugs, cisplatin, carboplatin, and oxaliplatin, prevail in the treatment of cancer, but new platinum agents have been very slow to enter the clinic. Recently, however, there has been a surge of activity, based on a great deal of mechanistic information, aimed at developing nonclassical platinum complexes that operate via mechanisms of action distinct from those of the approved drugs. The use of nanodelivery devices has also grown, and many different strategies have been explored to incorporate platinum warheads into nanomedicine constructs. In this Review, we discuss these efforts to create the next generation of platinum anticancer drugs. The introduction provides the reader with a brief overview of the use, development, and mechanism of action of the approved platinum drugs to provide the context in which more recent research has flourished. We then describe approaches that explore nonclassical platinum(II) complexes with trans geometry or with a monofunctional coordination mode, polynuclear platinum(II) compounds, platinum(IV) prodrugs, dual-threat agents, and photoactivatable platinum(IV) complexes. Nanoparticles designed to deliver platinum(IV) complexes will also be discussed, including carbon nanotubes, carbon nanoparticles, gold nanoparticles, quantum dots, upconversion nanoparticles, and polymeric micelles. Additional nanoformulations, including supramolecular self-assembled structures, proteins, peptides, metal-organic frameworks, and coordination polymers, will then be described. Finally, the significant clinical progress made by nanoparticle formulations of platinum(II) agents will be reviewed. We anticipate that such a synthesis of disparate research efforts will not only help to generate new drug development ideas and strategies, but also will reflect our optimism that the next generation of approved platinum cancer drugs is about to arrive.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,775
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Electrophoretic Analysis and Purification of Fluorescent Single-Walled Carbon Nanotube Fragments
Xu, X., Ray, R., Gu, Y., Ploehn, H. J., Gearheart, L., Raker, K., & Scrivens, W. A. (2004) · Journal of the American Chemical Society · doi:10.1021/ja040082h · Cited by 5,323
Quantum-Sized Carbon Dots for Bright and Colorful Photoluminescence
Sun, Y.-P., Zhou, B., Lin, Y., Wang, W., Fernando, K. A. S., Pathak, P., Meziani, M. J., Harruff, B. A., Wang, X., Wang, H., et al. (2006) · Journal of the American Chemical Society · doi:10.1021/ja062677d · Cited by 5,114
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Platinum Compounds: a New Class of Potent Antitumour Agents
ROSENBERG, B., VANCAMP, L., TROSKO, J. E., & MANSOUR, V. H. (1969) · Nature · doi:10.1038/222385a0 · Cited by 3,972
Cited by
Recent Strategies to Develop Innovative Photosensitizers for Enhanced Photodynamic Therapy
Pham, T. C., Nguyen, V.-N., Choi, Y., Lee, S., & Yoon, J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00381 · Cited by 1,813
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
The side effects of platinum-based chemotherapy drugs: a review for chemists
Oun, R., Moussa, Y. E., & Wheate, N. J. (2018) · Dalton Transactions · doi:10.1039/c8dt00838h · Cited by 1,737
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Zeng, L., Gupta, P., Chen, Y., Wang, E., Ji, L., Chao, H., & Chen, Z.-S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00195a · Cited by 1,017
The rediscovery of platinum-based cancer therapy
Rottenberg, S., Disler, C., & Perego, P. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00308-y · Cited by 972
Metal complexes in cancer therapy – an update from drug design perspective
Ndagi, U., Mhlongo, N., & Soliman, M. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s119488 · Cited by 935
Chandrakala, V., Aruna, V., & Angajala, G. (2022) · Emergent Materials · doi:10.1007/s42247-021-00335-x · Cited by 768
Toxicity of Metal Compounds: Knowledge and Myths
Egorova, K. S., & Ananikov, V. P. (2017) · Organometallics · doi:10.1021/acs.organomet.7b00605 · Cited by 703
Metallodrugs are unique: opportunities and challenges of discovery and development
Anthony, E. J., Bolitho, E. M., Bridgewater, H. E., Carter, O. W. L., Donnelly, J. M., Imberti, C., Lant, E. C., Lermyte, F., Needham, R. J., Palau, M., et al. (2020) · Chemical Science · doi:10.1039/d0sc04082g · Cited by 692
Zhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 677
Ma, P., Xiao, H., Yu, C., Liu, J., Cheng, Z., Song, H., Zhang, X., Li, C., Wang, J., Gu, Z., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04269 · Cited by 649
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Shen, Z., Liu, T., Li, Y., Lau, J., Yang, Z., Fan, W., Zhou, Z., Shi, C., Ke, C., Bregadze, V. I., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b06201 · Cited by 633
Allocati, N., Masulli, M., Di Ilio, C., & Federici, L. (2018) · Oncogenesis · doi:10.1038/s41389-017-0025-3 · Cited by 625
Metal complexes as a promising source for new antibiotics
Frei, A., Zuegg, J., Elliott, A. G., Baker, M., Braese, S., Brown, C., Chen, F., G. Dowson, C., Dujardin, G., Jung, N., et al. (2020) · Chemical Science · doi:10.1039/c9sc06460e · Cited by 543
Hypoxia-targeted drug delivery
Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00304a · Cited by 542
Carbon Dots for In Vivo Bioimaging and Theranostics
Du, J., Xu, N., Fan, J., Sun, W., & Peng, X. (2019) · Small · doi:10.1002/smll.201805087 · Cited by 488
Jeyaraj, M., Gurunathan, S., Qasim, M., Kang, M.-H., & Kim, J.-H. (2019) · Nanomaterials · doi:10.3390/nano9121719 · Cited by 481
Platinum nanoparticles in nanobiomedicine
Pedone, D., Moglianetti, M., De Luca, E., Bardi, G., & Pompa, P. P. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00152e · Cited by 454
Ren, Z., Sun, S., Sun, R., Cui, G., Hong, L., Rao, B., Li, A., Yu, Z., Kan, Q., & Mao, Z. (2020) · Advanced Materials · doi:10.1002/adma.201906024 · Cited by 446
New Designs for Phototherapeutic Transition Metal Complexes
Imberti, C., Zhang, P., Huang, H., & Sadler, P. J. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201905171 · Cited by 443
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Classification of Metal-Based Drugs according to Their Mechanisms of Action
Boros, E., Dyson, P. J., & Gasser, G. (2020) · Chem · doi:10.1016/j.chempr.2019.10.013 · Cited by 437
Carbon Dots in Bioimaging, Biosensing and Therapeutics: A Comprehensive Review
Wang, B., Cai, H., Waterhouse, G. I. N., Qu, X., Yang, B., & Lu, S. (2022) · Small Science · doi:10.1002/smsc.202200012 · Cited by 411
Dai, Y., Yang, Z., Cheng, S., Wang, Z., Zhang, R., Zhu, G., Wang, Z., Yung, B. C., Tian, R., Jacobson, O., et al. (2018) · Advanced Materials · doi:10.1002/adma.201704877 · Cited by 409
Noble Metal Nanomaterials for NIR‐Triggered Photothermal Therapy in Cancer
Lv, Z., He, S., Wang, Y., & Zhu, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202001806 · Cited by 398
Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications
Chung, Y. H., Cai, H., & Steinmetz, N. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.024 · Cited by 391
Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B. (2021) · MedComm · doi:10.1002/mco2.55 · Cited by 387
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Cyclometalated iridium(III) luminescent complexes in therapy and phototherapy
Zamora, A., Vigueras, G., Rodríguez, V., Santana, M. D., & Ruiz, J. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.01.010 · Cited by 345
Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318
New keys for old locks: carborane-containing drugs as platforms for mechanism-based therapies
Stockmann, P., Gozzi, M., Kuhnert, R., Sárosi, M. B., & Hey-Hawkins, E. (2019) · Chemical Society Reviews · doi:10.1039/c9cs00197b · Cited by 317
Carbon dots as a new class of nanomedicines: Opportunities and challenges
Wang, B., Song, H., Qu, X., Chang, J., Yang, B., & Lu, S. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214010 · Cited by 305
DNA hydrogel-based gene editing and drug delivery systems
Mo, F., Jiang, K., Zhao, D., Wang, Y., Song, J., & Tan, W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.018 · Cited by 304
The design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy
Han, H.-H., Wang, H.-M., Jangili, P., Li, M., Wu, L., Zang, Y., Sedgwick, A. C., Li, J., He, X.-P., James, T. D., et al. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00673a · Cited by 299
Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future
Sen, S., Won, M., Levine, M. S., Noh, Y., Sedgwick, A. C., Kim, J. S., Sessler, J. L., & Arambula, J. F. (2022) · Chemical Society Reviews · doi:10.1039/d1cs00417d · Cited by 297
Auría-Soro, C., Nesma, T., Juanes-Velasco, P., Landeira-Viñuela, A., Fidalgo-Gomez, H., Acebes-Fernandez, V., Gongora, R., Almendral Parra, M. J., Manzano-Roman, R., & Fuentes, M. (2019) · Nanomaterials · doi:10.3390/nano9101365 · Cited by 289
Platinum(iv) anticancer prodrugs – hypotheses and facts
Gibson, D. (2016) · Dalton Transactions · doi:10.1039/c6dt01414c · Cited by 286
Mechanisms of Chemotherapy-Induced Neurotoxicity
Was, H., Borkowska, A., Bagues, A., Tu, L., Liu, J. Y. H., Lu, Z., Rudd, J. A., Nurgali, K., & Abalo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.750507 · Cited by 285
Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium
Konkankit, C. C., Marker, S. C., Knopf, K. M., & Wilson, J. J. (2018) · Dalton Transactions · doi:10.1039/c8dt01858h · Cited by 284
Redox‐Active Metal Complexes for Anticancer Therapy
Zhang, P., & Sadler, P. J. (2017) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.201600908 · Cited by 274
Glutathione-Responsive Prodrug Nanoparticles for Effective Drug Delivery and Cancer Therapy
Ling, X., Tu, J., Wang, J., Shajii, A., Kong, N., Feng, C., Zhang, Y., Yu, M., Xie, T., Bharwani, Z., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b06400 · Cited by 263
Sun, Y., Ding, F., Zhou, Z., Li, C., Pu, M., Xu, Y., Zhan, Y., Lu, X., Li, H., Yang, G., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817021116 · Cited by 165
Li, C., Pang, Y., Xu, Y., Lu, M., Tu, L., Li, Q., Sharma, A., Guo, Z., Li, X., & Sun, Y. (2023) · Chemical Society Reviews · doi:10.1039/d3cs00227f · Cited by 157
Huang, Y., Sun, G., Sun, X., Li, F., Zhao, L., Zhong, R., & Peng, Y. (2020) · Cancers · doi:10.3390/cancers12113332 · Cited by 124
Ferroptosis promotes sonodynamic therapy: a platinum( ii )–indocyanine sonosensitizer
Lai, Y., Lu, N., Ouyang, A., Zhang, Q., & Zhang, P. (2022) · Chemical Science · doi:10.1039/d2sc02597c · Cited by 91
Rhaman, M. M., Islam, M. R., Akash, S., Mim, M., Noor alam, M., Nepovimova, E., Valis, M., Kuca, K., & Sharma, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.989471 · Cited by 63
Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy
Liu, P., Hao, L., Liu, M., & Hu, S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1161472 · Cited by 58
NIR‐II Emissive Ru(II) Metallacycle Assisting Fluorescence Imaging and Cancer Therapy
Fan, Y., Li, C., Bai, S., Ma, X., Yang, J., Guan, X., & Sun, Y. (2022) · Small · doi:10.1002/smll.202201625 · Cited by 51
Nanoscale Mixed-Ligand Metal–Organic Framework for X-ray Stimulated Cancer Therapy
Zhen, W., Xu, Z., Mao, Y., McCleary, C., Jiang, X., Weichselbaum, R. R., & Lin, W. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c12140 · Cited by 37
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
“1), which have each gained approval in Japan, China, and South Korea, respectively [13].”
Metadata
- Authors
- Johnstone, T. C., Suntharalingam, K., & Lippard, S. J.
- Venue
- Chemical Reviews
- Publisher
- American Chemical Society (ACS)
- Published
- 2016-02-11
- Volume
- 116
- Issue
- 5
- Pages
- 3436-3486
- ISSN
- 0009-2665 (ISSN-L)
- 1520-6890
- OpenAlex
- W2282989227
- Cited by
- 2,485
- References
- 332
- FWCI
- 32.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.